Introduction {#S0001}
============

Pain management is a human right of all patients, regardless of the nature and origin of pain (cancer pain, non-cancer chronic pain or acute trauma pain). This concept can be found in various reports and standards from the United Nations and other regional human rights organizations, and has direct implications on the practice of medicine and on the access to pain management resources.[@CIT0001]

Acute trauma pain has usually limited duration and has a rapid onset caused by a specific event.[@CIT0002] Trauma patients frequently report pain: up to 70% in the pre-hospital setting[@CIT0003],[@CIT0004] and 60--90% in the emergency department (ED). Pain itself is one of the main reasons why patients seek treatment from the ED.[@CIT0005]--[@CIT0007]

Besides ethical considerations, pain relief is a therapeutic endpoint per se,[@CIT0005] and an efficient management of acute trauma pain is a medical need: pain can be an obstacle to effective trauma treatment, since a patient with pain may be unable to provide his medical history, may have movement restrictions, and may be agitated, frustrated, or aggressive. The under-treatment of acute pain may result in tachycardia, hypertension, delayed recovery, inability to sleep, reduced mobility, worse quality of life, reduced immunity, and pain chronification.[@CIT0008]--[@CIT0010]

However, acute trauma pain is often overlooked, and not adequately assessed, and/or undertreated (oligoanalgesia), both in pre-hospital and ED settings.[@CIT0004],[@CIT0010]--[@CIT0015] Inadequate assessment and under-treatment of acute pain may be attributed to a number of reasons, including lack of specific training, unavailability of analgesic drugs, reluctance to prescribe certain drugs (e.g., opioids), failure to adhere to pain management guidelines or protocols, overcrowding of the ED.[@CIT0010],[@CIT0011],[@CIT0015]--[@CIT0022]

The availability of a non-narcotic, well-tolerated, rapid-acting, effective and easy to use treatment option may help overcome at least some of these barriers and improve acute trauma pain management.

Standard Pharmacological Treatment of Acute Trauma Pain {#S0002}
=======================================================

Current options for the management of acute pain in trauma settings include a plethora of different opioid and non-opioid drugs, available in many formulations and administered via different routes ([Table 1](#T0001){ref-type="table"}). The choice of the most appropriate pain management strategy should take into consideration pain severity, setting (e.g., ED -- pre-hospital -- hostile environment), patient's characteristics, and availability of drugs and/or personnel able to prescribe and administer analgesics.[@CIT0023]Table 1Commonly Used Pharmacological Treatments for Acute Trauma Pain\*DrugAdministration RouteIndicationNotesNitrous oxideInhaledModerate painTo be used in patients not at risk for pneumothorax or other situations where gas diffusion to body cavities may be dangerousParacetamolIV\
PR\
OralMild to moderate painTo be used with caution in patients with hepatic or renal impairment;\
May be combined with opioidsNon steroidal anti inflammatory drugs (NSAIDs)IV\
OralMild to moderate painMay delay healing of fractures and soft tissue injuries; not to be administered to elderly or renally impaired patientsDipyrone (metamizole)Oral\
IV\
SCModerate to severe painOnly available in some countries due to potentially life-threatening blood disordersOpioidsOral\
IV\
SC\
IM\
IN\
OM/SLModerate to severe painA vast class of drugs that can be used to treat different degrees of pain, based on individual characteristics; in order to reduce opioid dose while obtaining analgesia, they can be combined with other agents (eg paracetamol)KetamineIV\
IM\
INModerate to severe pain[^1][^2]

There is no consolidated pain management practice throughout Europe, and treatment choice may vary greatly between countries and even within the same country, based on Regional or institutional guidelines. The Guidelines for the management of acute pain in emergency situations recently released by the European Society for Emergency Medicine (EUSEM) may help unify pain management strategies and grant patients access to pain relief.[@CIT0023]

Inhaled Methoxyflurane {#S0003}
======================

Methoxyflurane is a highly volatile hydrocarbon and is administered through a portable inhaler. It has an effective and rapid analgesic effect and is indicated as an emergency treatment for moderate to severe pain in adult conscious patients with trauma and associated pain. However the exact mechanism of action is not known.

Low-dose (3 mL) methoxyflurane has recently become available in Europe. Treatment must be supervised by a healthcare professional and it is self-administered through patient-controlled analgesia. In the emergency setting, key advantages are represented by the easy handling of the formulation and the rapid onset of action.

The active ingredient is administered through a disposable inhaler (Penthrox^®^, 3 mL dose, Medical Developments International, Scoresby, Australia): liquid methoxyflurane contained in a 3 mL vial is absorbed by a polypropylene wick and immediately vaporizes. The patient inhales methoxyflurane from the mouthpiece and exhales through an active carbon chamber connected to the device, so that bystanders are not exposed to the drug. Each inhaler dispenses 3 mL of methoxyflurane. The maximum analgesic dose is 2 x 3 mL in 24 hours, and the second 3 mL bottle should only be used where needed. Administration on consecutive days is not recommended, and the total dose in a week should not exceed 15 mL.[@CIT0024]

Methoxyflurane has been used as an inhaled anesthetic starting in the 1960s but was discontinued in this setting in the late 1970s, since anesthetic doses were associated with nephrotoxicity and hepatotoxicity.[@CIT0025]--[@CIT0027] Methoxyflurane remained in use in Australia and New Zealand at sub-anesthetic doses as an analgesic, and has an established safety profile having been administered to over six million patients. Methoxyflurane is contraindicated for anesthetic purposes, and in patients with specific conditions and characteristics ([Box 1](#T0002){ref-type="table"}).[@CIT0024]Box 1Contraindications to Inhaled MethoxyfluraneUse as an anaesthetic agent.Hypersensitivity to methoxyflurane, any fluorinated anaesthetic or to butylated hydroxytoluene E321 (stabiliser).Malignant hyperthermia: patients who are known to be or genetically susceptible to malignant hyperthermia.Patients with a history of severe adverse reactions after being administered with inhaled anaesthetics.Patients with a known family history of severe adverse reactions after being administered with inhaled anaesthetics.Patients who have a history of showing signs of liver damage after previous methoxyflurane use or halogenated hydrocarbon anaesthesiaClinically significant renal impairment.Altered level of consciousness due to any cause including head injury, drugs, or alcohol.Clinically evident cardiovascular instability.Clinically evident respiratory depression.[^3]

Recently methoxyflurane has been approved in Europe for the relief of moderate to severe trauma pain in adult conscious patients, based on the results of the STOP! Phase III study.

The following paragraph summarizes the main studies, completed or ongoing in Europe, following a meeting where investigators discussed key data from each study, and intends to provide a narrative review. A systematic literature review has not been conducted.

European Clinical Trials {#S0004}
========================

STOP! Study -- Methoxyflurane vs. Placebo {#S0004-S2001}
-----------------------------------------

STOP! (ClinicalTrials.gov Identifier: NCT01420159) was a Phase 3, randomized, double blind trial comparing inhaled methoxyflurane to placebo in the ED setting. In this study, 300 patients (of whom 210 were adults ≥18 years of age) with moderate (Numeric Rating Scale \[NRS\] 4--7) trauma (burn, contusion, dislocation, fracture, injury due to foreign body, laceration) pain were randomized 1:1 to receive an inhaler with 3 mL of methoxyflurane or placebo. The patient could request a second inhaler, if necessary. Patients treated with methoxyflurane reported significantly greater and faster reduction in pain scores as compared to placebo: the overall difference between the methoxyflurane and placebo arms was −15.1 mm on the VAS scale (95% CI −19.2 to −11.0; p\<0.0001), with the greatest effect being observed at 15 min (−18.5 mm). Pain relief was reported by 87.2% of patients on methoxyflurane, with a median time to first pain relief of 4 minutes (95% CI 2.0 to 5.0). The majority of patients in the methoxyflurane arm (84.6%) reported their first pain relief within 10 inhalations (1--5 inhalations: 49.7%; 6--10 inhalations: 34.9%). No serious toxicities were observed, and the main safety findings were transient headache and dizziness. Both patients and health care professionals expressed satisfaction with methoxyflurane.[@CIT0028]

The STOP! Study was instrumental in establishing the efficacy and safety profile of inhaled methoxyflurane in controlling trauma pain, yet a comparison to commonly used analgesics in terms of efficacy was missing, therefore additional trials with an active comparator arm were conducted.

[Table 2](#T0003){ref-type="table"} provides a summary of the study designs and outcomes of the clinical studies of inhaled methoxyflurane included in this discussion.Table 2Summary of Inhaled Methoxyflurane Study Design and OutcomesStudy Name (Country) Trial Registration NumberStudy DesignControl ArmEfficacySafetyCoffey 2014, STOP! (UK) NCT01420159[@CIT0028]Phase 3, randomized, double blind, multicenter, placebo controlledPlaceboOverall pain reduction: −15.1 mm on the VAS scale (95% CI −19.2 to −11.0; p\<0.0001); median time to first pain relief 4 minutes (95% CI 2.0 to 5.0).Headache, dizzinessBorobia 2020, inMEDIATE (Spain) NCT03256903[@CIT0029]Phase 3b, randomized, open-label, multicenter, active-controlledStandard analgesic treatment (investigator's choice)Overall pain reduction −2.47 on the NRS scale (difference vs the control arm: 1.00; 95% CI 0.84 to 1.32); median time to first pain relief 3.17 minutesDizziness, somnolence and nausea; 1 case of severe dizzinessMercadante 2019, MEDITA (Italy) NCT03585374[@CIT0030]Phase 3b, randomized, open-label, multicenter, active-controlledStandard analgesic treatment (per protocol)Pain reduction on the VAS scale in the first 10 minutes: - 5.94 mm (95% CI - 8.83, - 3.06 mm; p\<0.001); time to first pain relief 9 minutesNo serious adverse events reportedRicard-Hibon 2020, penASAP (France) NCT03798899[@CIT0031]Phase 3b, randomized, open-label, multicenter, placebo-controlledMethoxyflurane or placebo as add-on therapy to standard analgesic treatment (investigator's choice)Median time to pain relief 35 minutes (not achieved in the control arm)No new safety signalsMarinangeli 2018, METEORA (Italy)[@CIT0032]Phase 3b, prospective, single-arm, multicenter trial-NRNR[^4][^5]

inMEDIATE Study -- Methoxyflurane vs. Active Therapy According to Investigator's Choice {#S0004-S2002}
---------------------------------------------------------------------------------------

inMEDIATE was a phase 3b, randomized, multicenter, open-label trial (ClinicalTrials.gov Identifier: NCT03256903) that compared inhaled methoxyflurane to standard pain management therapies as per investigator choice (1:1 randomization) during the first 20 minutes of administration in patients presenting to Spanish EDs with moderate to severe trauma pain (≥4 on the NRS). Traumas were represented by: contusion, fracture, swelling, dislocation, laceration, burn. The study enrolled 305 patients. In the comparator arm 70% of patients received intravenous (IV - NSAIDs in most cases) analgesia, and 9.4% were treated with opioids. Pain relief, as measured by the decrease in NRS pain score from baseline, was significantly greater in the methoxyflurane arm at all timepoints (5, 10, 15 and 20 minutes), regardless of baseline pain intensity and class of comparator analgesic. The global reduction in pain scores on the NRS scale during the first 20 minutes was 2.47 with methoxyflurane, versus 1.39 in the control arm (difference 1.00; 95% CI 0.84 to 1.32), and the proportion of responders, defined as patients who experienced a reduction of at least 30% in pain intensity, was significantly greater in the methoxyflurane arm (87.9% versus 57.7% in the control group). The median time to first pain relief was shorter in the methoxyflurane arm (3.17 minutes, versus 10.00 minutes with standard analgesic treatment), and patients on methoxyflurane spent less time in the ED compared to those who received standard treatment.

Patients and health care professionals expressed greater satisfaction in pain reduction and in comfort of treatment with methoxyflurane than with standard analgesics: methoxyflurane exceeded patients' expectations in 77% of cases (vs 38% for standard analgesic treatment) and clinicians' expectations in 72% of cases (vs 19% for standard analgesic treatment). Methoxyflurane was well tolerated in the inMEDIATE study; the reported adverse events were dizziness, somnolence and nausea, and were mild or moderate in intensity, except for one case of severe treatment-related dizziness.[@CIT0029]

MEDITA Study -- Methoxyflurane vs. Active Therapy According to Study Protocol {#S0004-S2003}
-----------------------------------------------------------------------------

MEDITA, a phase 3b, randomized, multicenter, open-label, active-controlled clinical trial (ClinicalTrials.gov Identifier: NCT03585374), enrolled 270 patients with a single trauma (fracture, dislocation, crushing or contusion) based on clinical suspicion. As in the inMEDIATE trial inhaled methoxyflurane was compared to standard analgesic treatment (SAT), but in this case the comparator drugs were defined by protocol: intravenous (IV) paracetamol or ketoprofen in moderate pain (NRS 4--6) and IV morphine in severe pain (NRS ≥7). The primary outcome was the change in pain score on the VAS scale from randomization (baseline) to 3, 5 and 10 minutes. During the first 10 minutes from randomization, patients on methoxyflurane reported a significantly greater pain reduction compared to patients on SAT (adjusted mean treatment difference - 5.94 mm; 95% CI - 8.83, - 3.06 mm; p\<0.001). Similar results were obtained in the patient subgroups defined by pain intensity at baseline (moderate pain: - 5.97 mm; 95% CI - 9.55, - 2.39 mm; p = 0.001; severe pain: - 5.54 mm; 95% CI - 10.49, - 0.59 mm; p = 0.029) in a post-hoc exploratory analysis.

The time to first pain relief was reported by 82.7% of patients on methoxyflurane and by 78.9% on SAT; even against the strong comparator drugs in the SAT arm, inhaled methoxyflurane provided a more rapid relief from pain (9 min; 95% CI 7.72, 10.28 min vs 15 min; 95% CI 14.17,15.83 min). Patients provided a higher rating of methoxyflurane efficacy as compared to SAT ("Excellent", "Very Good" or "Good": 72.7% vs. 60.9%; p = 0.001), while physicians were asked about the practicality of the different interventions and rated methoxyflurane as "Excellent", "Very Good" or "Good" in a significantly higher proportion with respect to SAT (90.3% vs. 64.4%; p\<0.001). Overall, 17% of patients on methoxyflurane experienced adverse events, none were serious.[@CIT0030]

PenASAP Study -- Methoxyflurane as Part of Multi-Modal Analgesia {#S0004-S2004}
----------------------------------------------------------------

In the French PenASAP study (ClinicalTrials.gov Identifier: NCT03798899), trauma patients with moderate to severe pain were randomized 1:1 to receive either methoxyflurane or placebo as an add-on therapy to the standard of care, as defined by the investigator. The data presented at the 2019 EUSEM congress show that the addition of methoxyflurane to standard analgesics is effective in relieving trauma pain (contusion, fracture, sprain, wound, dislocation, muscular injury, burn); the primary endpoint of median time to pain relief (defined as 30mm or less on the visual analogue scale) was 35 minutes in the methoxyflurane arm, while pain relief was not achieved in the control arm; no new safety signals were reported. While indirectly confirming that trauma pain undertreatment is still an unresolved issue in many EDs across Europe, the results of the PenASAP study establish inhaled methoxyflurane as a viable option in the context of multi-modal pain management strategies in trauma patients.[@CIT0031]

METEORA Study -- Methoxyflurane in Hostile Environments {#S0004-S2005}
-------------------------------------------------------

METEORA, a phase 3b, prospective, single-arm, multicenter trial, was designed to assess whether inhaled methoxyflurane is effective, safe and practical in treating trauma pain (fracture, dislocation, crushing or contusion) in hostile environments, given its specific characteristics (portability, easy use and rapid pain relief). This currently ongoing study will enroll approximately 200 patients with a single limb trauma (based on clinical suspicion) and moderate to severe pain in the context of rescue missions performed by the Helicopter Emergency Medical Service (HEMS) in Italy. Pain intensity will be measured on the VAS scale at baseline (start of methoxyflurane inhalation), 5, 10, 15, 20, 30, 45 and 60 minutes and when positioning the patient on a spinal board or stretcher, and also on the NRS scale at baseline and at 10 minutes. Patients will rate methoxyflurane efficacy and health care professionals will rate practicality at two timepoints (30 and 60 minutes). The primary endpoint of the METEORA study is the proportion of trauma patients who achieve at least 30% reduction in pain score on the VAS scale within 10 minutes from methoxyflurane inhalation.[@CIT0032]

Practicality of Inhaled Methoxyflurane {#S0005}
======================================

Pre-Hospital Setting {#S0005-S2001}
--------------------

The methoxyflurane inhaler is small and lightweight and can be easily transported and stored at a wide range of temperatures (−20 to 40° Celsius). These characteristics make it fit for use in the pre-hospital setting, where practicality is necessary.

The quick onset of analgesia provided by methoxyflurane, besides relieving the patients, allows rapid intervention when the patient needs to be extricated to be transported to the ED and in case of dislocations or fractures.

In the emergency setting, inhaled analgesics represent a great advantage because a rapid intervention is required and the time it takes to administer IV analgesics may delay rescue operations and transfer to the ED. Venous access can be troublesome in emergency situations, thus reducing the chance to provide rapid relief to the suffering patient and causing reduced patient throughput and waste of resources.

Inhaled methoxyflurane is self-administered by the patient after a brief training and typically provides pain relief within 6--10 inhalations. It requires no cannulation or other invasive procedures.

In pre-hospital settings, where interventions are made by a variety of professionals (e.g., paramedics, mountain or water rescue, police, firemen) and physicians may not be present, the practical and safe administration route of methoxyflurane is a clear advantage.

Exhalation through the active carbon chamber adsorbs exhaled methoxyflurane, avoiding dispersion in the environment and exposure of nearby individuals. This can be an advantage in small, secluded spaces (e.g., ambulance, rescue mission helicopter) and in busy EDs.

Hospital Setting {#S0005-S2002}
----------------

In the hospital setting the availability of analgesics is wider and medical personnel are present. The choice of pain management strategy should therefore be based on the patient's specific needs and characteristics, as well as the risk/benefit profile of the available drugs.

Pain relief should be provided as quickly as possible; ideally, the triage nurse should perform pain assessment and provide analgesia where necessary as part of the triage protocol. Time to analgesia is not merely related to the time it takes for a drug to relieve the pain, but also to the time to prescribe, obtain and administer the drug. When patients present to the ED with severe trauma pain, opioids are an obvious choice in terms of efficacy, yet the administrative burden associated to the administration of controlled substances, the availability of personnel with specific training and qualifications, the necessity to monitor patients after administration and to manage opioid side effects may become barriers to opioid utilization in emergency situations.

Self-administration of analgesics by the patient can represent an advantage, both in terms of pain control and resource utilization. Fast and effective provision of analgesia can ultimately result in organizational advantages, by allowing higher patient throughput and reducing ED overcrowding.

Safety {#S0006}
======

Over forty years of experience with low-dose methoxyflurane in Australia and New Zealand and the recent European studies have established its favorable safety profile in the setting of acute trauma pain treatment. The common non-serious adverse reactions observed at analgesic doses are CNS type reactions such as dizziness and somnolence, and are generally easily reversible.[@CIT0024] Laboratory tests performed shortly after methoxyflurane administration in clinical trials revealed no evidence of nephrotoxicity or hepatotoxicity.[@CIT0028],[@CIT0029] Treatment with methoxyflurane had no clinically significant effects on cardiovascular or respiratory parameters.[@CIT0029] Methoxyflurane can be administered to trauma patients in need of pain relief, with no need of constant monitoring by health care professionals.

Organizational Impact {#S0007}
=====================

The organizational and financial impact of methoxyflurane for acute pain management in the context of moderate to severe pain in patients with trauma (fracture, dislocation and contusion) presenting to the ED in Italy is currently the object of quali-quantitative research (METAMORPHOSIS study -- see [Table 3](#T0004){ref-type="table"} for study design). The study is currently being conducted through a structured interview administered to 14 key opinion leaders (10 ED directors, 2 doctors, 2 nurses) within 10 EDs located in 8 Italian Regions.Table 3Summary of the METAMORPHOSIS Study DesignObjectiveSettingMethodsTo assess the organizational impact of the use of inhaled methoxyflurane in Emergency Departments in Italy10 emergency departmentsStructured interview administered to 14 key opinion leaders in 10 emergency departmentsTo assess the cost of the process of the administration of analgesic therapies in Emergency Departments in Italy3 emergency departmentsProcess analysis assessed through the expert opinion of 3 key opinion leaders in 3 emergency departments

The results of the analysis showed a positive organizational impact compared to the standard of care and this was related to an increase of the efficiency of the administration processes (not requiring intravenous administration and due to its "easy and simple way of use"), to a more rapid analgesic effect and to a reduced monitoring activity.

Rapid pain relief is also instrumental in establishing trust in the ED personnel by reducing patient stress and agitation. Considering patients' hospital pathway, the use of methoxyflurane would not inhibit the use of further therapies (due to the absence of drugs interactions) and would not limit patients' activities after discharge (as in the case of use of opioids). Considering the possibility to transport patients to other departments compared with analgesics administered by the IV route, inhaled methoxyflurane allows better safety and comfort with respect to patient transportation.

In terms of cost of administration and monitoring process, as estimated through process analysis based on expert opinion of clinicians involved in the research conducted at 3 of 10 participating EDs, the use of inhaled methoxyflurane compared with paracetamol IV plus morphine IV, would lead to a reduced use of human resources and consumables, with a lower cost per process of more than 30 € (not considering the cost of the device).

Finally, the use of inhaled methoxyflurane was associated with a positive acceptance by both health care professionals and patients (as reported by the key opinion leaders interviewed).

Discussion {#S0008}
==========

Fast and efficient management of moderate to severe pain in trauma patients is a medical need, yet oligoanalgesia remains a problem despite the availability of several therapeutic options.

The recent introduction of low-dose inhaled methoxyflurane represents a new approach to acute trauma pain treatment.

Several randomized controlled trials have been recently conducted, comparing methoxyflurane to placebo[@CIT0028] or to standard analgesic treatments[@CIT0029],[@CIT0030] (either defined by protocol or by the investigators) and in the context of multi-modal analgesia.[@CIT0031] All have reported consistent results: low-dose methoxyflurane is an effective analgesic and provides pain relief faster than the comparators (i.e., time to first pain relief 3--5 minutes; 6--10 inhalations). Methoxyflurane is generally well tolerated, with mild and transient adverse events (mainly headache and dizziness).

When patient and health care professional satisfaction was assessed, methoxyflurane scored higher points than the comparators in terms of pain control, comfort and ease of use.

Data from the control arms of the studies that compared methoxyflurane to standard treatment as per investigator choice also showed that trauma pain is often undertreated in current clinical practice, and there is no established standard of care (e.g., in the inMEDIATE study[@CIT0029] only 23% of the patients with severe pain \[\>7 on the NRS scale\] received opioids in the standard of care arm or as a rescue medication; in the PenASAP study[@CIT0031] patients in the control arm did not achieve pain control).

There are several barriers to effective trauma pain control, and they are not only complex but also generally associated with a lack of time and resources. The availability of a fast-acting, self-administered, well tolerated and effective non-narcotic alternative such as inhaled methoxyflurane represents a useful addition to current options, particularly in situations where flexibility, practicality of use and rapid effect are needed. In the pre-hospital setting inhaled methoxyflurane can be particularly useful since it is portable, non-flammable, and can be self-administered by the patients while the rescue personnel perform vital operations. The fast analgesic action enables the patient to be moved quickly and without excessive discomfort. Inhaled methoxyflurane is administered at fixed dose and requires no invasive procedures. The exhalation of methoxyflurane through an active carbon chamber reduces professional exposure to the drug and is an advantage in small spaces, such as an ambulance or a helicopter.

In the hospital setting, methoxyflurane may offer an organizational advantage, being fast and easy to administer, with reduced patient monitoring required. It could save resources by allowing ED personnel to perform other duties while the patient self-administers the drug under supervision. Methoxyflurane may be particularly useful for patients who present with traumas that are easy to treat when severe pain prevents procedures (e.g., dislocations and fractures).

Depending on local regulations, specific protocols could be necessary to allow non-medical staff to prescribe and administer inhaled methoxyflurane. Besides rescue staff at emergency scenes, this would also apply to the triage nurse who could perform pain assessment and prescribe methoxyflurane where appropriate, thus relieving the patient from pain as quickly as possible. Methoxyflurane does not interfere with other drugs, thus allowing the patient to receive other medications or anaesthetics if necessary.

Additional research on low-dose inhaled methoxyflurane could be useful to clearly establish its relative efficacy compared to opioids (including inhaled opioids) in patients with severe trauma pain, and in identifying the trauma patient profiles who could benefit the most from this acute pain treatment option. Finally, since METEORA[@CIT0032] and METAMORPHOSIS studies are not yet complete, it is not possible to draw definitive conclusions on the use of methoxyflurane in hostile environments and on the organizational impact.

Conclusion {#S0009}
==========

Low-dose methoxyflurane, administered through a portable, handheld, disposable device, is a well-tolerated and effective option in the management of acute, moderate to severe trauma pain in adult patients. Its ease of use, portability and fast action make it particularly useful in all the situations where rapid analgesia is required, including pre-hospital/hostile environments where practicality is necessary.
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[^1]: **Note:** \*In adult patients.

[^2]: **Abbreviations:** IV, intravenous; PR, per rectum; SC, subcutaneous; IM, intramuscular; IN, intranasal; OM/SL, oromucosal/sublingual.

[^3]: **Notes:** Penthrox 99.9% 3mL inhalation vapour, liquid. Summary of product characteristics. (Date of revision - Jan 2019). Electronic Medicines Compendium (emc). Available from: [<https://www.medicines.org.uk/emc/product/1939/smpc>]{.ul}. Accessed January 10, 2020.[@CIT0024]

[^4]: **Notes:** The METEORA study is currently ongoing and has not reported results yet.

[^5]: **Abbreviations:** CI, confidence interval; NR, not reported.
